
A research team led by Dr. Der-Yang Cho, Superintendent of China Medical University Hospital (Taiwan), in collaboration with Shine-On Biomedical Co., has developed the world’s first targeted exosome drug delivery platform aimed at HLA-G, marking a major milestone in the field of precision oncology. The novel platform, named SOB100, has completed preclinical studies and demonstrated promising efficacy in treating aggressive cancers such as breast cancer and glioblastoma.
當癌症悄然侵襲年幼生命,治療的每一步都格外艱辛,宛如一場與癌症比耐力又拚時間的馬拉松賽。年僅六歲的陳小妹妹確診神經母細胞瘤,且病灶已多處轉移。她在中國醫藥大學附設醫院接受三週連續質子治療,目前腫瘤已受到控制,病況穩定,正持續接受後續免疫治療。相較傳統放射線療法,質子治療能精準治療腫瘤、降低副作用,尤其適合發育中的兒童。中醫大附醫團隊結合專業與關懷,以先進設備與「醫者人母心」的溫柔守護,為病童點亮重獲健康的希望之路。
本院訂2026年1月,將對於已逾保存年限之成年病人不活動病歷資料,辦理銷毀作業,特此公告。